Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Angiotensin Receptor Blockers
100%
Candesartan
100%
Clinical Profile
100%
Candesartan Cilexetil
100%
Clinical Trials
40%
Antihypertensive Drugs
40%
Heart Failure
40%
Adult Patients
40%
Highly Selective
20%
Placebo
20%
Risk Reduction
20%
Blood Pressure Control
20%
Once-daily
20%
Angiotensin II (Ang II)
20%
Blood Pressure Regulation
20%
Cardiovascular Mortality
20%
Type 2 Diabetes Mellitus (T2DM)
20%
Renal Failure
20%
Metabolic Syndrome
20%
Renin-angiotensin-aldosterone System
20%
Patients with Hypertension
20%
Renin-angiotensin System
20%
Migraine
20%
Losartan
20%
Tolerability
20%
Retinopathy
20%
Clinical Evidence
20%
Heart Stroke
20%
High Potency
20%
Current Market
20%
Telmisartan
20%
Valsartan
20%
Arterial Stiffness
20%
Long Duration of Action
20%
Antihypertensive Compounds
20%
Market Leader
20%
Volume Homeostasis
20%
Angiotensin II Type 1 Receptor Antagonist
20%
Blood Pressure Treatment
20%
Kidney Impairment
20%
Pharmacology, Toxicology and Pharmaceutical Science
Angiotensin Receptor Antagonist
100%
Candesartan Hexetil
100%
Candesartan
100%
Clinical Trial
40%
Angiotensin
40%
Antihypertensive Agent
40%
Renin
40%
Cerebrovascular Accident
40%
Congestive Heart Failure
40%
Placebo
20%
Angiotensin II
20%
Kidney Failure
20%
Metabolic Syndrome X
20%
Aldosterone
20%
Angiotensin 1 Receptor Antagonist
20%
Cardiovascular Mortality
20%
Migraine
20%
Losartan
20%
Tolerability
20%
Retinopathy
20%
Telmisartan
20%
Valsartan
20%
Non Insulin Dependent Diabetes Mellitus
20%
Antihypertensive Drug
20%